Bristol Myers Squibb licenses Antibody-Drug Conjugate technology from Lonza

Waiv enters collaboration with Daiichi Sankyo to deliver AI-derived biomarkers for ADC program

Tacalyx secures €11 million to advance lead TACA-targeting ADC programme toward the clinic

Servier completes the acquisition of Day One Biopharmaceuticals

CrossBridge Bio enters an agreement to be acquired by Eli Lilly to advance next-generation dual-payload...

3B Pharmaceuticals and TetraKit Technologies announce strategic collaboration for joint radioligand therapy (RLT) development

Akari Therapeutics announces strategic partnership with WuXi XDC to advance development of its novel ADC...

Sidewinder Therapeutics announces $137 million series B financing to advance precision bispecific ADCs into clinical...

Zai Lab announces global clinical trial collaboration and supply agreement to evaluate novel DLL3 ADC,...